Partner Nate Lacktman was quoted in a FierceHealthcare article, “OIG identifies $3.7M in improper Medicare telehealth payments, which could lead to more scrutiny for providers,” about an audit of Medicare payments for telehealth services.
As a result of the findings, Lacktman said, providers can expect more scrutiny of telehealth claims moving forward. “The big takeaway is to spend more attention to billing compliance,” he said. “The telehealth arrangements 5-10 years ago were built on a self-pay cash model. Now they are expanding and that’s really going to change the game for a lot of providers.”
As a result of the findings, Lacktman said, providers can expect more scrutiny of telehealth claims moving forward. “The big takeaway is to spend more attention to billing compliance,” he said. “The telehealth arrangements 5-10 years ago were built on a self-pay cash model. Now they are expanding and that’s really going to change the game for a lot of providers.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”